COVID-19: Advances in Pathophysiology and Therapeutics
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 506
Special Issue Editor
Interests: HIV, sepsis; COVID-19; multi-drug-resistant pathogens; urogenital infections; immunology of infection
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
While the official pandemic status of COVID-19 may have concluded, the impact of the disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is far from over. In fact, there are ongoing lessons to be learned and areas of research yet to be explored. The complexity of the disease, from its intricate pathophysiology and wide array of clinical presentations to the multiple therapeutic options available, continues to challenge the medical community. This Special Issue aims to serve as a comprehensive platform for the latest research findings that explore the advances in understanding the pathophysiology and developing new therapeutic interventions for COVID-19.
The objectives of this Special Issue are as follows: firstly, to collate research articles, reviews, and case reports that contribute to an evolving understanding of the immunological mechanisms specific to COVID-19; secondly, to feature evidence-based, clinically relevant updates on available treatment modalities and explore the current pharmacological landscape; and lastly, to facilitate a multidisciplinary discussion that aligns research outcomes with practical clinical applications, including the management of COVID-19 and its associated comorbid conditions.
Topics of interest may include:
Molecular and cellular mechanisms of SARS-CoV-2 infection and immune response underlying COVID-19;
Emerging therapeutic avenues and translational research findings that translate into clinical practice;
Biomarkers for disease severity and prognosis;
Advances in antiviral agents, monoclonal antibodies, and other pharmacotherapeutics;
Therapeutic management of comorbid conditions in COVID-19 patients;
Evaluations on the efficacy of existing and novel treatments.
Dr. Karolina Akinosoglou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- SARS-CoV-2
- pathophysiology
- immunology
- pharmacotherapy
- biomarkers
- comorbidities
- clinical management
- disease severity
- treatment efficacy
